Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 231,900 shares, a drop of 5.7% from the August 31st total of 245,800 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 7.8% of the shares of the company are sold short.
Hedge Funds Weigh In On Clearmind Medicine
A hedge fund recently raised its stake in Clearmind Medicine stock. AdvisorShares Investments LLC raised its stake in shares of Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 14.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 128,641 shares of the company’s stock after purchasing an additional 15,948 shares during the quarter. AdvisorShares Investments LLC owned 7.60% of Clearmind Medicine worth $214,000 as of its most recent filing with the SEC. 96.05% of the stock is owned by hedge funds and other institutional investors.
Clearmind Medicine Stock Down 0.8 %
Clearmind Medicine stock opened at $1.21 on Wednesday. Clearmind Medicine has a 52 week low of $0.92 and a 52 week high of $10.35. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.31.
Clearmind Medicine Company Profile
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
See Also
- Five stocks we like better than Clearmind Medicine
- How to Calculate Inflation Rate
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Why Are These Companies Considered Blue Chips?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Dividend Capture Strategy: What You Need to Know
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.